Cybin Inc., a Phase 3 clinical-stage neuropsychiatry company developing proprietary drug discovery platforms and delivery systems to transform mental healthcare, announced that George Tziras, chief business officer, will present at the Jefferies Global Healthcare Conference. The conference will be held November 17-20, 2025, in London, United Kingdom.
The company is committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. With promising class-leading data, Cybin is working to change the mental health treatment landscape through the introduction of novel drugs that provide effective and durable results for patients.
Cybin is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder. This investigational treatment has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, potentially accelerating its development and review process. The company is also advancing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder.
Additionally, Cybin maintains a research pipeline of investigational, 5-HT-receptor focused compounds, expanding its potential impact on mental health treatment. Founded in 2019, the company has established operational presence across Canada, the United States, the United Kingdom and Ireland, positioning it as a global player in neuropsychiatry development.
The latest news and updates relating to CYBN are available in the company's newsroom at https://ibn.fm/CYBN. The full press release detailing the conference presentation can be viewed at https://ibn.fm/bb3sl.
This presentation at a major global healthcare conference represents a significant opportunity for Cybin to showcase its clinical progress and pipeline developments to the international investment and healthcare communities. The timing coincides with important Phase 3 data readouts for CYB003 in major depressive disorder, potentially positioning the company as a leader in the emerging psychedelic-based mental health treatment space.
The mental health treatment landscape continues to face substantial challenges with many patients experiencing inadequate responses to current therapies. Cybin's approach to developing novel compounds with potentially improved efficacy and durability could address critical gaps in mental healthcare. The company's progress through advanced clinical trials and regulatory milestones like Breakthrough Therapy Designation demonstrates the growing recognition of these innovative approaches within the medical and regulatory communities.
